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Rare variation has a key role in the genetic etiology of
complex traits. Genetically isolated populations have
been established as a powerful resource for novel
locus discovery and they combine advantageous
characteristics that can be leveraged to expedite
discovery. Genome-wide genotyping approaches
coupled with sequencing efforts have transformed the
landscape of disease genomics and highlight the
potentially significant contribution of studies in
founder populations.ways underpinning T2D were achieved through theComplex trait locus discovery in isolated
populations
Genetically isolated or founder populations have recently
returned to the fore of genetic association studies as
valuable resources for complex trait gene identification
[1]. Population isolates have well-documented character-
istics, including reduced phenotypic, environmental and
genetic heterogeneity, that can aid in the detection of
rare variants associated with complex traits. In isolated
populations, where a relatively small number of individ-
uals found a new population, rare variants that were
present in the founders can drift up in frequency as the
population expands, thus increasing power for genetic
association studies. The small effective population size,
which remains small over time, leads to increased levels
of homozygosity and linkage disequilibrium. In addition,
isolated population cohorts often provide the opportun-
ity to recall subjects by genotype, access detailed genea-
logical records, obtain linkage to health records and
follow the cohort longitudinally.
Recent successes in the literature have highlighted
how these advantageous characteristics can help with
disease gene mapping. Researchers studying the Ice-
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genome-wide genotyping and whole genome sequencing
(WGS) approaches, for complex disease gene mapping
[2,3]. In Iceland, numerous novel loci for complex dis-
eases, such as type 2 diabetes (T2D) and prostate cancer
[4,5], have been identified through a combination of
WGS and long-range phasing-assisted imputation on a
genome-wide genotype scaffold, together with calcula-
tion of genotype probabilities in approximately 300,000
untyped individuals by making use of the extended ge-
nealogical information available.
More recently, novel insights into the biological path-
study of a Greenlandic founder population [6]. A non-
sense variant in the TBC1D4 gene was found to be
strongly associated with postprandial hyperglycemia, im-
paired glucose tolerance and T2D. These unique insights
into the mechanism conferring muscle insulin resistance
for this subset of T2D was afforded by studying the
small Greenlandic population, which has experienced a
dramatic increase in T2D prevalence, and recalling indi-
viduals based on their TBC1D4 variant status. This poly-
morphism is common in Greenland (17% minor allele
frequency), but vanishingly rare in other global popula-
tions (only encountered in one Japanese individual in
the 1000 Genomes Project data). This work elegantly
demonstrates the value of combining the genetic charac-
teristics of founder populations with the potential to re-
contact participants for further follow-up of promising
results. Studies in extensively phenotyped founder popu-
lation cohorts, such as the Amish, have also demon-
strated the value of combining unique population
characteristics with recall of subjects to increase our un-
derstanding of disease etiopathology. The Old Order
Amish are a cultural isolate and geographically localized,
genetically homogeneous population with extensive ge-
nealogical records available. This deeply phenotyped co-
hort has been the subject of long-term genetic studies.
For example, in 2008, Pollin et al. [7] reported a mis-
sense variant (R19X) that abolishes expression of theThe licensee has exclusive rights to distribute this article, in any medium, for 12
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tective phenotype (higher high-density lipoprotein and
lower blood triglyceride levels).
Notably, the same missense cardioprotective variant
was also found in an independent isolated population
from Greece in the HELIC-MANOLIS study [8]. Resi-
dents of the mountainous Mylopotamos villages on
Crete have a high fat content diet but anecdotally display
lower levels of, for example, T2D complications com-
pared with the general population. The R19X APOC3
variant was carried by approximately 4% of the individ-
uals studied and reached genome-wide statistical signifi-
cance with a sample size of fewer than 1,300. Discovery
of the same effect in the general population would have
required over 50 times the number of subjects. Large-
scale studies of over 110,000 individuals of European
descent have recently also established an association of
rare variants in the APOC3 locus with protection against
high triglyceride levels and coronary artery disease [9].
APOC3 is now becoming a poster child for the power
afforded by founder populations and clearly demon-
strates the generalizability of findings in isolates into
more cosmopolitan populations.
A prime example of how founder population charac-
teristics coupled with linkage to medical records can ac-
celerate discovery was recently produced by studying the
Finnish population [10]. In a whole exome sequencing
study of about 3,000 Finns, Lim et al. first established
that the Finns have fewer variable sites overall but more
loss-of-function variants compared with non-Finnish
European individuals, and subsequently identified robust
associations with key traits of medical relevance. Linkage
to national medical records resulted in the demonstra-
tion that splice variants in the LPA gene that are associ-
ated with low levels of plasma lipoprotein(a) confer
protection against cardiovascular disease.
Future directions
Going forward, it is clear that founder populations can
provide a unique and powerful resource for the identifi-
cation of low frequency and rare variants of direct
medical consequence. Power to detect association is
demonstrably boosted for individual sequence variants
that have drifted up in frequency. In addition, power to
detect a significant accumulation of rare variants at par-
ticular loci is further increased in founder populations as
neutral rare variation may be lost from the haplotype
pool. In this context, meta-analysis at the locus level
across different isolates is posited to be important for
establishing burden of proof, although this principle
requires empirical substantiation. Historically, the trans-
ferability of findings in isolates across to more cosmo-
politan populations has been a topic of debate. However,
there is an accrual of emerging examples of locidiscovered in founder populations that are more widely
generalizable, with replication of signals achieved in di-
verse sample sets [4,5,7-9]. Furthermore, invaluable and
unprecedented insights into disease pathogenesis can be
afforded by findings restricted to genetically isolated
populations, as exemplified by the elegant metabolic trait
study in Greenland [6]. Decreasing costs for deep whole
genome sequencing and the increasing availability of
deeply phenotyped genetically isolated cohorts sets the
scene for further success stories in the near future.
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